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While multimodality therapy has become the
standard for most solid tumors, the mainstay of
therapy for melanoma remains surgical. This
includes not only early stage disease, but
advanced melanoma as well. The surgical
approach to melanoma has changed dramati-
cally, with a trend towards less aggressive resec-
tion of the primary tumor, and towards a more
aggressive approach to regional and metastat-
ic disease. Melanoma surgery has been altered
by our knowledge of the biology of the disease,
and the results of well-designed, prospective
randomized trials. Conversely, new surgical
approaches have expanded our understand-
ing of melanoma biology, and new random-
ized trials are needed to further define the opti-
mal surgical approach. This article will review
the evolution of melanoma surgery and the
evidence behind today’s recommendations. 
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Cancer has evolved over the past centuryfrom existing as primarily a surgical dis-
ease to one treated in this day by a multidis-
ciplinary approach. Today, few solid tumors,
with the exception of the earliest-stage dis-
ease, are treated by surgery alone. Melanoma
stands out as an exception at all stages.
Mainstays in the therapy of most malignan-
cies, chemotherapy and radiation therapy
play extremely limited roles in the manage-
ment of melanoma. Similarly, despite a
tremendous interest in their potential for treat-
ment, biologic and immunologic therapies
have not to date significantly impacted out-
comes in melanoma. Surgery thus remains
the primary treatment for both thin, local-
ized malignant melanoma as well as for
advanced melanoma.
While the need for surgery has remained
constant, the nature of that surgery has
changed considerably over that time.  It cur-
rently targets 3 arms of treatment: the pri-
mary tumor, the nodal basin, and when fea-
sible, stage IV disease. Historically, treatment
of the primary tumor began with narrow exci-
sion. Review of outcomes, and high rates of
local and regional recurrence, led next to
wide radical excisions, but failure to improve
overall survival led to a reversion back to
moderate margins. Management of the
regional nodal basin has also evolved and
continues to be a source of controversy
among clinicians. Even further, the role of
surgery in stage IV disease is expanding
beyond palliation towards curative extirpa-
tion. 
These changes in the surgical management
of melanoma have been the result of both
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our increased knowledge of the natural biol-
ogy of this disease and prospective, ran-
domized trials designed to answer specific
questions regarding specific treatment
options. This article will review the role of
surgery in the management of cutaneous
melanoma, the evidence behind our current
practice, and the questions that remain.
Surgery and the primary melanoma
Excisional biopsy of melanoma with nar-
row and negative margins is inadequate treat-
ment, associated with local recurrence rates
in the range of 30% to 60%.1 Since first
described by William Norris in 1857, the wide
radical excision has remained the mainstay of
therapy for localized melanoma.2 Wide rad-
ical excision consists of excising an adequate
margin of normal appearing skin down to
underlying fascia. Historically, the muscular
fascia was excised with the specimen. There
existed some belief, however, that removing
the fascia might promote the dissemination of
tumor cells and increase the recurrence rate.3
Although this has never been addressed in a
prospective trial, a retrospective trial of 202
patients showed no difference in recurrence
with the removal of the fascia.4 Current prac-
tice involves dissection down to, but not
including the fascia with the resection spec-
imen. 
The definition of an adequate margin for
wide radical excision has changed over time.
In 1907, Handley recommended a margin of
1 inch. This was based both on the failure of
the present approaches to cure the disease
and on microscopic examination of strips of
adjacent tissue from autopsy studies.5, 6 In
the later half of the 20th century, the recom-
mended margins increased to 4 or 5cm based
on the discovery of melanocytes and
microsatellites beyond the excision site.7, 8 In
some cases, this involved a radical en bloc
resection of the regional nodal basins.
This radical excision, despite the morbidity
involved, remained the treatment for
melanoma until an interest in gathering sci-
entific data to support these recommenda-
tions via clinical trials emerged. Five ran-
domized trials demonstrated no difference in
survival between conservative margins and
wide margins (Table I 9-16). However, the stud-
ies differed greatly in both the entry criteria and
the margins of excision. Three trials compared
2 cm margins to either 4 cm or 5 cm margins,
while 2 trials compared 1 cm margins with 3
cm margins. Our present recommendations
are based on the data from these randomized
trials, with the margin of excision based on
the Breslow thickness of the primary tumor.
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TABLE I.—Randomized trials of wide versus narrow excision for malignant melanoma.
Trial Author No. Breslow depth Arms Follow-up Outcomes
World Health Organization, Veronesi 9, 10 612 ≤2 mm 1 cm vs 3 cm 8 years NSD
Melanoma Program 10 OS, DFS, LRR
Intergroup Melanoma Surgical Trial Balch 11, 12 486 1-4 mm 2 cm vs 4 cm 10 years NSD
OS, LRR
Swedish Melanoma Group Ringborg 13, 14 989 0.8-2 mm 2 cm vs 4 cm 11 years NSD
OS, DFS, LRR





French Cooperative Group Banzet 16 319 ≤2 mm 2 cm vs 5 cm 4 NSD
OS, DFS
OS: overall survival; DFS: disease-free survival; LRR: local-regional recurrence; NSD: no significant difference; HR: hazard ratio
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Resection margins for thin (<1 mm) me-
lanoma
The World Health Organization (WHO)
Melanoma Group prospectively randomized
612 patients with melanomas less than 2 mm
thick to receive excision with either 1 cm
(narrow) or 3 cm (wide) margins.9, 10 In the
group of patients who had melanoma <1 mm
(356 patients), there were no local recur-
rences whether they had 1 cm or 3 cm mar-
gins of excision. There was no difference
between the 2 groups in the disease-free and
overall survival rates after 15 years.17 The
WHO Melanoma Group trial clearly demon-
strated that a 1 cm margin provides excel-
lent control for melanomas 1 mm and less. 
Resection margins for melanoma >2 mm
Most of the trials included thicker
melanomas. A multi-institutional prospective
randomized trial from France demonstrated
no difference in either local recurrence rate
or survival between patients who had a 5 cm
margin or a 2 cm margin.16, 17 This trial includ-
ed 319 patients with melanomas 2 mm or
greater in thickness. 
The Intergroup Melanoma Committee con-
ducted a randomized prospective study eval-
uating 2 cm versus 4 cm margins in 468
patients with intermediate thickness melano-
mas (1-4 mm).11, 12 There was a statistically
significant difference in the need for skin
grafts between the groups, with 46% of the 4
cm group requiring skin grafts versus 11% of
the 2 cm group. With a ten-year median fol-
low-up, there was no significant difference in
recurrence between the groups. 
The Swedish Melanoma Study Group com-
pared 2 cm versus 5 cm margins of excision
in 989 patients with melanomas between 0.8
and 2 mm thick. There were local recurrences
in 1% of patients, equally distributed between
the 2 study arms, and no differences in recur-
rence-free or overall survival.13
Cumulatively, these studies all demonstrate
that a 2 cm margin for intermediate-thick-
ness melanomas (1-4 mm) is appropriate to
significantly minimize the risks of both recur-
rence and the need for skin grafting. These
studies do not, however, answer the question
of whether 1 cm margins may also be ade-
quate for intermediate thickness melanoma. 
Thomas et al. 15 reported the result of a
trial of 900 patients with melanoma >2 mm
randomized between 1 and 3 cm margins
performed by the UK Melanoma Study
Group, the British Association of Plastic
Surgeons, the Institute of Cancer Research
and the Scottish Cancer Therapy Network.
Although there was no statistically significant
difference in overall survival, there was an
increase in locoregional recurrences with 1
cm margins, with a hazard ratio of 1.26 (95%
confidence interval, 1 to 1.59; P=0.05). There
was also a trend towards decreased mela-
noma-specific survival, with a hazard ratio
of 1.24 (95% CI, 0.96 to 1.61; P=0.1). This tri-
al demonstrated that there is an increased
risk of locoregional recurrence with 1 cm
margins. It also suggested that this margin
may be associated with increased mortality.
Based on these results, the trial concluded
that a margin of 1 cm is inadequate for
melanomas greater than 2 mm in Breslow
thickness.  Notably, though, the increased
recurrence rate was primarily restricted to
regional recurrences in the draining nodal
basin. It is unclear whether this risk would still
exist today with the routine application of
lymphatic mapping and sentinel lymph node
biopsy (SLNB).
The margins of excision necessary for
melanomas greater than 4 mm remains con-
troversial, as this population was not repre-
sented in the randomized trials. While a more
aggressive surgical resection may be war-
ranted given the known biologic aggressive-
ness of thick melanomas, this must be tem-
pered against the higher propensity of these
lesions to have already metastasized, mini-
mizing the impact of local control on overall
survival. The optimum approach for this
group has yet to be well determined, but the
present recommendations are margins of at
least 2 cm.
Resection margins for melanoma between 1
and 2 mm
The randomized trials demonstrate that
melanomas less than 1 mm can be safely
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resected with a 1 cm margin, and that
melanomas >2 mm should be resected with
a minimum of a 2 cm margin. What about
melanoma between 1 and 2 mm? While the
studies show that 2 cm margins are appro-
priate, there is little data to answer whether
1 cm margins would be appropriate. The
only study of 1 cm versus 3 cm margins that
included patients with melanoma between
1 and 2 mm melanoma was the World Health
Organization Melanoma Group trial. As
described above, this trial included patients
melanomas less than 2 mm thick to receive
excision with either 1 cm (narrow) or 3 cm
(wide) margins.9, 10 While there were no local
recurrences among patients with melanomas
<1 mm who underwent either wide or narrow
excision, in the subset of patients with
melanomas 1.1 to 2 mm thick, there was a
2.7% local recurrence rate in  the 1 cm resec-
tion margin group. No local recurrences were
seen in the same group of patients who
received 3 cm margins. There was no differ-
ence in survival between the 2 groups. Based
on these results, the standard recommenda-
tion is to obtain 2 cm margins when possible,
but if this would be exceptionally difficult or
require a skin graft for closure, narrower mar-
gins (no less than 1 cm) would be appropri-
ate (Table II).
Surgery and the regional nodal basin
Lymph node dissection for clinically evident
nodal disease
All patients with melanoma should under-
go a complete physical examination with par-
ticular attention being paid to the regional
draining lymph node basins, as approxi-
mately 5% of patients will have clinically
apparent nodal involvement at the time of
diagnosis.18 Patients who have previously
undergone a wide excision may recur with
palpable adenopathy evident on exam, and
occasional patients present with nodal metas-
tases in the absence of a detectable primary
melanoma. Palpable enlarged nodes (gener-
ally 1-1.5 cm in maximum diameter), or nodes
that are hard or fixed to adjacent structures
must be considered suspicious for metastat-
ic involvement. Metastatic nodal involvement
should be verified with a fine needle aspira-
tion (FNA) biopsy. Excisional biopsy is
reserved for those situations where the lymph
node is clinically suspicious but the FNA
biopsy results are inconclusive. 
Complications of an open biopsy (sero-
ma, infection, scarring) can interfere with the
performance of the subsequent lymph node
dissection. Previous interventions in the
regional basin have also been associated with
an increase in melanoma recurrence after
radical dissection.19 For both oncologic and
functional reasons, if an excisional biopsy is
performed, the incision should be oriented in
a way that it can be readily re-excised during
the complete lymph node dissection.
Patients with biopsy proven palpable nodal
involvement should undergo a complete
lymph node dissection in addition to the wide
local excision of the primary tumor. This pro-
cedure may be curative. Prior to proceeding,
however, a work-up must be undertaken for
the presence of metastatic disease. This
begins with a detailed history and physical
examination, including a thorough review of
symptoms focusing on symptoms consistent
with metastases. At the very least, patients
with clinically involved nodes should have a
chest radiograph and serum lactate dehy-
drogenase (LDH) level evaluated. Abnorma-
lities on history, physical, CXR or LDH
deserve a further search for metastatic dis-
ease. 
For the asymptomatic patient, many sur-
geons advocate routine imaging. This may
consist of either a CT scan of the chest,
abdomen and pelvis or a whole-body PET
scan. Both of these imaging studies have
been described to upstage stage III patients
to stage IV, thereby altering the choice of
surgical therapy.20-22 Some surgeons feel that
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TABLE II.—Recommended margins of excision for pri-
mary melanoma.
Melanoma in situ 0.5 cm
Less than or equal to 1 mm 1 cm
1 to 2 mm 1 to 2 cm
2 to 4 mm 2 cm
> 4 mm at least 2 cm
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PET scanning is superior to CT scans, while
others have suggested the false-positive rates
for PET imaging is too high to make it a reli-
able choice. CT scanning has the additional
advantage of providing additional anatomic
information that the surgeon may find useful
to plan the dissection. One example in par-
ticular would be the presence of enlarged
pelvic lymph nodes; this finding might well
convert an inguinal node dissection to an ili-
ac-inguinal node dissection.
AXILLARY LYMPH NODE DISSECTION
For patients with palpable disease in the
axilla, the axillary lymph node dissection
(ALND) should include levels I, II, and III
nodes to provide the best regional control.
Some surgeons, however, include level III
only when suspicious nodes are present.23-25 In
a thin patient, with adequate mobilization and
anterior retraction of the pectoralis major and
minor muscles, it may be possible to ade-
quately dissect the level III nodes without
dividing the pectoralis minor muscle. This may
involve dissection between the pectoralis
major and minor muscles to adequately
include the level III nodes, which lie medial to
the pectoralis minor muscle. In most patients,
however, it is necessary to divide the pec-
toralis minor muscle. The extent of dissection,
as measured by the number of nodes
removed, has been correlated with improved
five-year survival in one retrospective study.26
Other variations in technique affect both
the regional recurrence rate and the mor-
bidity of axillary dissection. Preservation of
the long thoracic and thoracodorsal nerves is
considered routine, and injury to these nerves
should be extremely rare in experienced
hands. The intercostobrachial nerves may
also be preserved, however most surgeons
routinely resect these when the dissection is
being performed for palpable disease. Some
authors have advocated a more extensive
dissection, including removal of the supra-
axillary fat pad, although this greatly increas-
es the morbidity by exposing the brachial
plexus. Brachial plexus injuries, although
rare, can be devastating complications of this
procedure. Because there is no evidence that
removal of the fat pad improves survival, this
procedure is not routinely recommended.
Lymphedema remains the most common
complication of ALND. While many surgeons
skeletonize the axillary vein during the dis-
section, others have suggested that this may
increase the rate of lymphedema. Lawton et
al.27 proposed preservation of the fascia from
the pectoralis and latissimus dorsi muscles
to decrease postoperative lymphedema.
Definitive studies addressing variations in
technique and their impact on outcome have
not been performed. In experienced hands,
the lymphedema rate after ALND should be
between 5% and 12%.24, 28, 29
GROIN DISSECTION
Groin dissections are associated with a
much higher overall complication rate; 50%
to 64% compared to 14% to 17% for axillary
lymph node dissection.30, 31 More than 20% of
patients will have chronic lymphedema.32-34
Wound complications, including skin flap
necrosis, wound dehiscense and surgical site
infections, are quite common.
For patients with inguinal disease, the
extent of lymphadenectomy is more contro-
versial. Whether simply an inguinofemoral
dissection (superficial) should be performed
(with the inguinal ligament being the supe-
rior boundary of dissection) or the iliac nodes
should be included is a matter of debate giv-
en the higher rate of complications involved
with the pelvic dissection. Some surgeons
advocate routinely performing the addition-
al iliac dissection (deep) for patients with
clinically apparent inguinal disease. Others
limit iliac dissection to only patients with a
positive Cloquet’s node or multiple (3 or
more) involved nodes. The drawback of
using Cloquet’s node as a deciding factor for
dissection boundaries is its limited ability to
predict the involvement of pelvic lymph
nodes.35 Still others do not perform an iliac
dissection unless there is radiographic evi-
dence of pelvic adenopathy. 
A retrospective review of 104 patients who
underwent superficial versus superficial plus
deep dissection demonstrated no influence of
the deep dissection on locoregional recur-
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rence or survival.36 Another retrospective
study of 227 patients who had either super-
ficial or superficial and deep dissections also
failed to demonstrated a survival advantage
associated with the extent of surgery, prompt-
ing the conclusion that pelvic dissection
should be limited to patients with clinical
evidence of disease.37 Five-year survival rates
of 24% to 35% have been reported for
patients with pelvic involvement who under-
go superficial and deep dissection.37, 38
If an iliac dissection is to be performed
with the inguinofemoral dissection, this can
be accomplished through one skin incision by
obliquely dividing the external and internal
oblique muscles to expose the pelvic
retroperitoneum, or alternatively by dividing
the inguinal ligament. This may be particu-
larly useful in cases of disease low in the
pelvis along the distal external iliac vessels.
The inguinal ligament may be divided either
over the femoral vessels, which is technical-
ly simpler, or at the anterior superior iliac
spine, which may be associated with better
wound healing. 
CERVICAL DISSECTION
The gold standard for treating regional dis-
ease in the neck has been the radical neck
dissection (RND); removal of levels I-V as well
as the sternocleidomastoid muscle, internal
jugular vein and spinal accessory nerve. Given
the extent of the structures removed, RND can
be associated with significant morbidity. A
modified radical neck dissection (MRND), also
described as a functional neck dissection,
includes preservation of any or all of those
structures. Several authors have reported no
appreciable difference in the risk of regional
recurrence with MRND versus RND.39-41 A
more selective approach has therefore been
advocated, basing the dissection on the loca-
tion of the involved nodes or primary lesion.41
Sentinel lymph node biopsy as a
staging procedure
While there is little argument as to the
potential benefit of a lymph node dissection
for patients with clinically evident disease,
the optimal management of patients without
clinically evident disease remains controver-
sial. Prior to the advent of SLNB, many advo-
cated the performance of an elective lymph
node dissection (ELND) for patients without
clinical evidence of nodal metastases in order
to assess for microscopic metastatic disease.
Although ELND provides important prog-
nostic information, this is only of benefit if
there are adjuvant therapies to offer the
patient who is found to harbor metastases.
Given the high rate of complications associ-
ated with ELND, the morbidity of it is hard-
ly justified on the basis of accurate staging
alone. 
The management of patients with melano-
ma changed considerably after SLNB was
described by Morton et al.42 There now exists
a reliable method for the identification and
removal of the primary lymph node drain-
ing the site of a cutaneous melanoma, one
that accurately determines whether tumor
cells have metastasized to that respective
lymph node basin.43-45 Regional recurrence
after sentinel node biopsy is infrequent, and
has a greatly decreased morbidity as com-
pared to ELND. 46, 47
SLNB possesses the further advantage of
allowing for a more detailed histological
examination than ELND. Identification of
micrometastases in sentinel nodes is carried
out by careful sectioning of the node (step-
sectioning) as well as the use of immuno-
histochemical staining with anti-S-100, anti-
MART-1, or HMB-45 (anti-gp100) antibod-
ies.48 Clinically, even microscopic foci of
melanoma detected only by immunohisto-
chemical staining are significant. With this
increased sensitivity, sentinel lymph node
status is the most important predictor of sur-
vival for patients with melanoma. Patients
with a negative sentinel node are over 6 times
more likely to survive than those with a pos-
itive sentinel lymph node (SLN), making the
predictive impact of sentinel node status
much greater than any other prognostic fac-
tor.49
SLNB plays a central role in staging the
regional lymph nodes and is the standard of
care in many major melanoma centers.44, 50
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Currently, the compelling prognostic value
of the nodal status makes SLNB indispensable
for accurate staging, and thus obligates it to
be a key component of future studies exam-
ining adjuvant therapy. Which patients should
undergo SLNB? Cascinelli et al.50 reported
SLN positivity rates of 16% in lesions thicker
than 1 mm. Among the 829 patients in a
WHO study, positivity rates of 2% (<1 mm),
7% (1-1.99 mm), 13% (2-2.99 mm), and 31%
(>3 mm) were reported. In addition to tumor
thickness, other factors such as tumor ulcer-
ation, young patient age, and mitotic rate
have been shown to be associated with SLN
positivity.49, 51, 52 Based on these data, as well
as on additional corroborating studies, the
SLNB procedure should be routinely consid-
ered for primary melanomas deeper than 1
mm. It may be selectively applied for tumors
1 mm or less, when other worrisome fea-
tures are present.
The same arguments against ELND may
be made against SLNB: the cost and morbid-
ity, albeit lower, are not justified simply to
obtain accurate staging information. Since
the introduction of SLNB, however, adjuvant
therapy in the form of high-dose interferon
(HDI) has become available for the treatment
of high-risk melanoma. Although the use of
HDI is controversial, the available evidence
demonstrates an improvement in disease-
free survival as well as a likely improvement
in overall survival.53-56 Justification of its use
and appropriate patient selection are issues
beyond the scope of this article. If the patient
is a candidate for adjuvant interferon or par-
ticipation in a clinical trial for other adjuvant
therapies, SLNB is certainly justified in order
to identify high-risk individuals. Regardless,
the primary argument in favor of SLNB is the
potential improvement in long-term outcome
associated with the early eradication of micro-
scopic disease.
Lymph node dissection for
microscopic disease
Complete lymph node dissection in
patients without nodal disease was first advo-
cated by Snow in 1892.57 The argument favor-
ing ELND theorized that of the patients with
occult metastases in the regional basin, some
may have no distant disease at diagnosis, but
could develop secondary metastases from
occult lymph node metastases during the
interval between diagnosis of the primary
melanoma and progression to clinically evi-
dent nodal disease. Eradicating that micro-
scopic disease from the lymph nodes before
spread occurs would prevent the develop-
ment of distant disease and thereby improve
survival. The exact impact of lymph node
dissection on survival, however, would
depend on the size of the target population.
If a large percentage of patients with micro-
scopic nodal disease already have concomi-
tant distant disease at diagnosis, or con-
versely, if only a small percentage of patients
with microscopic disease go on to develop
secondary metastases, then the impact on
survival would be quite small. As only
approximately 20% of patients are node pos-
itive, the impact of ELND on these subjects
would have to be quite large in order to see
a survival benefit for the entire group.
The argument for ELND was fueled by ret-
rospective data suggesting a survival benefit
existed. Two retrospective reviews compared
survival statistics for patients with localized
melanomas (stage I and II) who underwent
wide excision alone with those who under-
went wide excision plus ELND.58, 59 Both
reviews suggested that patients who under-
went wide excision plus ELND had a signif-
icantly higher survival rate than those who
had wide excision alone, even after the analy-
sis was stratified for tumor sites. As with all
retrospective research, though, any number
of unknown variables may have played a
role in the choice between ELND and obser-
vation. 
This data prompted 2 large prospective,
randomized trials to answer the question of
whether ELND provides a survival benefit.
The WHO Melanoma Group randomized 2
groups of patients to receive either wide exci-
sion plus ELND (n=267) or wide excision
with subsequent therapeutic lymphadenec-
tomy if clinically indicated (n=286).60 Analysis
of these data revealed no difference in sur-
vival between the 2 groups. With follow-up
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now at greater than 20 years, the WHO Trial
still shows no statistical improvement in either
survival or disease-free interval.17 The largest
trial to examine the issue was the Intergroup
Melanoma Surgical Program, which ran-
domized 740 stage I and II melanoma patients
to ELND or observation.61 Overall, there again
was no significant difference between the 2
groups. Long-term results confirmed no sig-
nificant ten-year survival difference between
ELND or observation (77% vs 73%, P=0.12).31
On the surface, this would seem to end
the discussion on whether we should be per-
forming ELND, or even SLNB, for melanoma.
Further assessment of the data, however, sug-
gests that there are subsets of patients who do
benefit from ELND. 
In the Intergroup trial, a significant reduc-
tion in mortality with ELND was seen for
patients with nonulcerated melanomas,
tumors between 1 and 2 mm, and limb
melanomas. It is possible that these subsets
represent patients who are less likely to have
distant disease in the presence of regional
disease, and thus might benefit from early
lymph node dissection. Further evidence is
provided from the WHO Program 14 Trial,
which compared ELND to observation for
patients with truncal melanomas. When the
survival of patients in the WHO Program 14
Trial with microscopic disease at ELND was
compared with those who had regional recur-
rences during observation, the survival was
significantly improved in the former group
(48.2% vs 26.6%, P=0.04). 62
This data suggests, but does not prove,
that lymph node dissection may benefit
patients with microscopic disease in the
lymph nodes, but not all clinically node neg-
ative patients. The SLN has provided a selec-
tive approach to complete lymph node dis-
section, sparing node-negative patients the
morbidity of the procedure, while offering
improved regional control and any potential
survival benefit to the node-positive patient.
The Multicenter Selective Lymphadenec-
tomy Trial-I is the only current prospective
randomized trial that specifically compares
wide excision alone to wide excision plus
SLNB, with complete node dissection for
patients with a positive SLN. The most recent
follow-up data was presented at the American
Society of Clinical Oncology (ASCO) meeting
in Orlando, Florida in May, 2005.63 The inter-
im results compared only those patients with
positive SLN, either those found to be posi-
tive on SLNB or those who recurred after
wide local excision alone. The seven-year
melanoma specific survival for patients who
had completion lymph node dissection
(CLND) for a positive SLN was 69%, com-
pared to 48% for patients undergoing delayed
CLND after nodal relapse (P=0.0034, RR=0.53,
95% CI 0.33,0.84). 
The evidence to date suggests that per-
forming SLNB plus CLND for a positive SLN
is unlikely to result in a survival advantage
when all patients are compared, but will
improve survival among the subset of patients
with occult lymph node metastases. Whether
this approach is worth the added cost will
require maturation of the data. When ana-
lyzed along with the use of adjuvant inter-
feron, it does appear to be cost-effective. 64
But is the completion node dissection nec-
essary? It is possible that SLNB alone will
identify patients at high risk, and in the sub-
set of patients for whom the SLN is the only
node that harbors disease, it in itself is ther-
apeutic. Additional positive non-sentinel
lymph nodes (NSN) are found in only 7-33%
of patients with a positive sentinel node.
Unfortunately, predicting which patients will
have residual disease in the NSN has proven
difficult.65-67 Even patients with the most
favorable primary melanomas have a sub-
stantial risk of additional disease in the basin.
The on-going Multicenter Selective Lympha-
denectomy Trial-II will help answer this ques-
tion by randomizing patients with a positive
SLN to CLND or observation. Until the final
results from these 2 trials are available, CLND
for a positive SLN remains the standard
approach.
Surgery for stage IV melanoma
The management of metastatic disease
from most cancers rarely falls into the domain
of the surgeon. Notable exceptions include
liver resection for colorectal metastases and
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pulmonary resection for sarcoma metastatic
to the lung, both of which may be associat-
ed with long-term survival. Distant site recur-
rences of melanoma are unpredictable,
though, and can occur in almost every major
organ or tissue. While most patients with
metastatic melanoma will not be candidates
for curative resection, complete surgical resec-
tion of melanoma metastases may be associ-
ated with an improvement in long-term sur-
vival. 
Selection of patients for curative resection
The five-year survival for patients with
stage IV melanoma is approximately 10%.
Not all stage IV disease is equivalent in prog-
nosis, however, so careful selection of stage
IV melanoma patients for consideration of
metastatectomy is imperative. Five-year sur-
vival rates as high as 35% have been report-
ed with proper patient selection. Several fac-
tors should be weighed into the decision to
resect metastatic disease, foremost being the
initial site of metastases. The new American
Joint Committee on Cancer (AJCC) staging
system groups metastatic melanoma into 3
subsets. M1a disease is defined as nonvis-
ceral metastases such as skin, subcutaneous
tissue or lymph nodes outside of the draining
basins. Patients with M1a disease have a 5
year melanoma specific survival rate of
approximately 19%.68 M1b disease is defined
as pulmonary metastases, and M1c disease
includes all nonpulmonary visceral metas-
tases. The survival rate for visceral disease
is lower than for M1a disease, at approxi-
mately 7% for M1b and 9% for M1c disease.
All patients with metastatic melanoma should
have a serum LDH level drawn, as this cor-
relates with distant disease. If elevated, it
leads to a classification of M1c disease regard-
less of the site of distant disease.
Other factors that deseve consideration
include the likelihood of a complete resec-
tion, the number of metastatic foci, the initial
stage of disease and the interval between pri-
mary therapy and distant recurrence. The
patient’s performance status, co-morbidities
and life expectancy are also considered. The
patient with the solitary, easily resected lesion
who is >2 years out from initial resection is an
ideal candidate for resection. The patient
with multiple metastases shortly after prima-
ry therapy presumed to have more aggressive
disease and is very unlikely to benefit from
surgical resection; other treatment options
should be explored. For patients on the fence,
one option is to treat the patient with sys-
temic therapy for 2 to 3 months and then re-
evaluate the patient. Patients who have a
response or remain stable may then proceed
to resection.
Preoperative evaluation begins with a thor-
ough history and physical examination,
including a complete review of systems
designed to elicit signs and symptoms of
additional metastatic disease. Blood count,
metabolic profile and serum LDH should be
obtained. Although LDH is clearly associated
with prognosis, it is unclear whether an ele-
vated LDH in a patient with what appears to
be resectable disease should preclude
surgery.68 A thorough search for the extent of
metastatic disease must be undertaken. Any
symptoms suggestive of metastatic disease
should prompt the appropriate additional
studies, such as MRI for symptoms consis-
tent with brain metastases. Asymptomatic
patients have typically been evaluated with a
CT scan of the chest, abdomen and pelvis.
However, recent studies have suggested that
18-flourodeoxyglucose positron emission
tomography (FDG-PET) should be obtained
to detect occult metastatic disease, and would
be the imaging study of choice in this situa-
tion.22, 69, 70
Resection of M1a disease
The most common site of distant metas-
tases are to remote areas of skin and soft tis-
sues, as well as to lymph nodes outside of the
draining basins. Patients with a solitary metas-
tasis to dermal or subcutaneous tissue have
a reasonable long-term prognosis.  There
should be no hesitancy to resect these
patients if the work-up reveals no addition-
al areas of disease. Patients with more exten-
sive M1a disease must be evaluated on a indi-
vidualized basis, taking into account both
the number and location of metastases and
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the disease-free interval. Several series have
reported impressive five-year survivals after
resection of M1a disease (Table III 71-74).
Resection of these lesions may also be pal-
liative, so erring on the side of an aggressive
surgical approach may be reasonable in the
appropriate setting. 
Resection of M1b disease
Fifteen percent to 30% of metastases from
malignant melanoma will occur in the lungs,
typically asymptomatically, and is detected
by either chest radiography or computed
tomography (CT). Most will not be candi-
dates for surgical resection because of either
multiple lesions or the presence of extrapul-
monary disease. The patient with the soli-
tary pulmonary metastasis, in the absence of
additional disease discovered on CT or PET
scan, should undergo resection. It is impor-
tant to remember that in the patient with a
history of melanoma and the new solitary
pulmonary nodule, this may not be a metas-
tases but a new primary lung cancer. When
more than one lesion is present, the deci-
sion to perform a pulmonary metastatectomy
necessitates consideration of the ability to
achieve a complete resection. The pulmonary
function and comorbidities of the patient as
well as the disease-free interval also play a
heavy role in this decision. In selected
patients, five-year survivals of 15% to 15%
may be achievable (Table IV73, 75-80). 
Resection of M1c disease
Visceral recurrences outside of the lung are
less likely to benefit from surgery, but resec-
tion may be appropriate for highly selected
patients. Although it is one of most common
malignancies to metastasize to the gastroin-
testinal tract, this is in actuality a relatively
rare occurrence. Patients with gastrointesti-
nal tract involvement are usually symptomatic,
with pain/obstruction, bleeding/anemia and
weight loss. Surgery is primarily palliative,
but may offer long-term survival (five-year
survivals of 5% to 10%).81-85 One series
demonstrated that long-term palliation could
be achieved in a majority of patients, and
patients who underwent complete resection
had a longer median survival than patients
who could not.86 Factors associated with a
poor outcome include short disease-free inter-
val or elevated serum LDH.83 Resection of
metastases to the spleen or liver have also
been described, although only rare patients
are candidates for that surgery. 87, 88
Brain metastases are common in melanoma
patients and are associated with an extreme-
ly poor prognosis. Patients may present with
headaches, focal neurologic deficits or
seizures; if left untreated they will experi-
ence rapid deterioration and death. Palliation
often involves whole brain irradiation, though
surgery or radiosurgery have been used with
reasonable results. Not only is palliation
achieved in a significant number of patients,
but several series describe median survivals
of 6 to 18 months, depending on the selection
criteria.89-94 Whether surgical resection should
be followed by whole-brain irradiation
remains controversial. The criteria used to
select patients include the number of lesions
and their accessibility. Patients with deep-
seated or multifocal lesions, while not good
surgical candidates, may be candidates for
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TABLE III.—Survival after complete resection of M1a
disease.
Author Year No. Site 5-year survival
(%)
Markowitz 71 1991 72 Lymph nodes 38
Markowitz 71 1991 60 Soft tissue 49
Gadd 72 1992 190 All 14
Karakousis 73 1994 23 Lymph nodes 22
Karakousis 73 1994 27 Subcutis 33
Meyer 74 2000 45 Lymph nodes 20
Meyer 74 2000 30 Skin/subcutis 17.8
TABLE IV.—Survival after complete resection of M1b
disease.
Author Year No. 5-year survival
(%)
Wong 75 1988 38 31
Gorenstein 76 1991 59 25
Harpole 77 1992 98 20
Karakousis 73 1994 39 14
Tafra 78 1995 106 27
La Hei 79 1996 83 22
Leo 80 2000 282 22
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stereotactic radiation techniques (gamma
knife). These consist of multiple convergent
beams that deliver a single high dose of radi-
ation to the lesion(s). 95, 96
Conclusions
In summary, surgery remains the corner-
stone of therapy for the treatment of both
primary and metastatic melanoma. It offers a
cure for primary melanoma when appropri-
ate resection margins are taken. Surgery also
plays a substantial role in the diagnosis and
treatment of regional disease, a role that has
changed significantly since the advent of
SLNB. Even when the spread of disease has
exceeded microscopic levels, surgery can not
only provide palliation, but prolong survival
if metastectomy is applied to an appropri-
ately selected patient population. The future
of melanoma therapy is hopeful; it holds
promise for adjuvant or neoadjuvant treat-
ments in the form of vaccines, new chemo-
therapies and biologic agents. The objectives
and outcomes of surgical intervention will
continue to change dramatically as these oth-
er therapies demonstrate their potential. Until
those roles are better defined and bear out
success, however, surgical therapy remains
the foundation of treatment for melanoma.
Riassunto
Il ruolo del chirurgo nella gestione del melanoma
Mentre la terapia multidisciplinare è diventata lo
standard per la maggior parte dei tumori solidi, per il
melanoma il trattamento è ancora imperniato sull’in-
tervento chirurgico. Questo è vero non solo per le fasi
precoci della malattia ma anche per quelle avanzate.
L’approccio chirurgico al melanoma è mutato radi-
calmente, indirizzandosi verso un’asportazione meno
aggressiva del tumore primario, accompagnata, però,
da un approccio più aggressivo nei confronti delle
metastasi. La chirurgia del melanoma è stata influen-
zata dalla comprensione dei meccanismi biologici
della malattia e dai dati emersi dagli studi clinici pro-
spettici e randomizzati appositamente disegnati.
Viceversa, i nuovi approcci chirurgici ci hanno con-
sentito di comprendere meglio la biologia del mela-
noma, ma sono necessari ulteriori studi randomizza-
ti per definire ulteriormente l’approccio chirurgico
ottimale. Questo articolo rivede l’evoluzione della
chirurgia del melanoma e sottolinea le evidenze che
sono alla base delle raccomandazioni attuali.
Parole chiave: Melanoma - Chirurgia - Linfonodo sen-
tinella - Biopsia linfonodale.
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